Zurich | Swiss group Lonza, which is one of the main suppliers of pharmaceutical laboratories, will open a new production line in the Netherlands to produce the Moderna vaccine, he said on Wednesday.
It will be installed at a plant located in Gelin, in the south of the country, and is due to enter service in late 2021, the Swiss group said in a press release.
It should be able to produce up to 300 million additional doses a year when it is operating at full capacity, Lonza said, which will strengthen its partnership with a US biotech company.
Last May, Lonza signed its first agreement with Moderna, providing a 10-year partnership for the production of the COVID vaccine, as well as other Moderna products in the future.
The Swiss group making active ingredients for vaccine production has since set up three production lines at its plant in Visp, Switzerland, and one at its plant in Portsmouth, USA in New Hampshire.
Faced with a shortage of vaccines, Lonza and Moderna have already expanded their partnership in April 2021 by signing a new agreement to create three additional production lines at their plant in Switzerland.